ICI-118,551
ICI-118,551 is a selective β2 adrenergic receptor (adrenoreceptor) antagonist or beta blocker. ICI binds to the β2 subtype with at least 100 times greater affinity than β1 or β3, the two other known subtypes of the beta adrenoceptor. The compound was developed by Imperial Chemical Industries, which was acquired by AkzoNobel in 2008.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
ICI-118,551
ICI-118,551 is a selective β2 adrenergic receptor (adrenoreceptor) antagonist or beta blocker. ICI binds to the β2 subtype with at least 100 times greater affinity than β1 or β3, the two other known subtypes of the beta adrenoceptor. The compound was developed by Imperial Chemical Industries, which was acquired by AkzoNobel in 2008.
has abstract
ICI 118551 ist ein β2-selektiv ...... n AkzoNobel übernommen worden.
@de
ICI-118,551 is a selective β2 ...... soluble to at least 2.5 mg/mL.
@en
IUPAC name
3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol
@en
Wikipage page ID
18,850,804
page length (characters) of wiki page
Wikipage revision ID
1,005,552,157
Link from a Wikipage to another Wikipage
ImageFile
@en
IUPACName
Verifiedfields
changed
@en
verifiedrevid
424,696,718
wikiPageUsesTemplate
comment
ICI 118551 ist ein β2-selektiv ...... n AkzoNobel übernommen worden.
@de
ICI-118,551 is a selective β2 ...... acquired by AkzoNobel in 2008.
@en
label
ICI 118551
@de
ICI-118,551
@en